Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: A meta-analysis of placebo-controlled randomised trials

The Lancet Neurology

Volumn 10, Issue 11, 2011, Pages 961-968

  Ryvlin, Philippe ^a,b   Cucherat, Michel ^b   Rheims, Sylvain ^a,b  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BRIVARACETAM; CARISBAMATE; CLOBAZAM; CLONAZEPAM; ESLICARBAZEPINE ACETATE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; LORAZEPAM; LOSIGAMONE; NALOXONE; OXCARBAZEPINE; PLACEBO; PREGABALIN; REMACEMIDE; RETIGABINE; RUFINAMIDE; TALAMPANEL; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ARTICLE; CAUSE OF DEATH; DRUG EFFICACY; EPILEPSY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SUDDEN DEATH; SUDDEN UNEXPECTED DEATH IN EPILEPSY;

ADULT; ANTICONVULSANTS; DEATH, SUDDEN; EPILEPSY; FEMALE; HUMANS; INCIDENCE; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 80054737737     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70193-4     Document Type: Article

References (43)

1. Sillanpaa M, Shinnar S Long-term mortality in childhood-onset epilepsy. N Engl J Med 2010, 363:2522-2529.
2. Mohanraj R, Norrie J, Stephen LJ, Kelly K, Hitiris N, Brodie MJ Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study. Lancet Neurol 2006, 5:481-487.
3. Tomson T, Nashef L, Ryvlin P Sudden unexpected death in epilepsy: current knowledge and future directions. Lancet Neurol 2008, 7:1021-1031.
4. Langan Y, Nashef L, Sander JW Case-control study of SUDEP. Neurology 2005, 64:1131-1133.
5. Leestma JE, Walczak TS, Hugues JR, Kalelkar MB, Teas SS A prospective study on sudden unexpected in epilepsy. Ann Neurol 1989, 26:195-203.
6. Tellez-Zenteno JF, Ronquillo LH, Wiebe S Sudden unexpected death in epilepsy: evidence-based analysis of incidence and risk factors. Epilepsy Res 2005, 65:101-115.
7. Walczak TS, Leppik IE, D'Amelio M, et al. Incidence and risk factors in sudden unexpected death in epilepsy: a prospective cohort study. Neurology 2001, 56:519-525.
8. Hesdorffer D, Tomson T, Benn E, et al. Combined analysis of risk factors for SUDEP. Epilepsia 2011, 52:115-159. for the ILAE Commission on Epidemiology; Subcommission on Mortality.
9. Nilsson L, Farahmand BY, Persson PG, Thiblin I, Tomson T Risk factors for sudden unexpected death in epilepsy: a case-control study. Lancet 1999, 353:888-893.
10. Pedley TA, Hauser WA Sudden death in epilepsy: a wake-up call for management. Lancet 2002, 359:1790-1791.
11. Epilepsy in the WHO European Region 2010, WHO, World Health Organization, Geneva, (accessed Oct 20, 2010). http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510.pdf.
12. Nashef L Sudden unexpected death in epilepsy: terminology and definitions. Epilepsia 1997, 38:S6-S8.
13. Annegers JF United States perspective on definitions and classifications. Epilepsia 1997, 38:S9-12.
14. Higgins JPT, Altman DG Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] 2011, The Cochrane Collaboration, (accessed May 1, 2011). http://www.cochrane-handbook.org, J.P.T. Higgins, S. Green (Eds.).
15. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007, 26:53-77.
16. Antiepileptic drugs and suicidality 2008, US Food and Drug Administration, FDA, (accessed May 1, 2011). http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM192556.pdf.
17. Zhang L, Huang J, Zhuang JH, Huang LQ, Zhao ZX Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly. J Int Med Res 2011, 39:408-415.
18. Halford JJ, Ben-Menachem E, Kwan P, et al. A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures. Epilepsia 2011, 52:816-825.
19. Boas J, Dam M, Friis ML, Kristensen O, Pedersen B, Gallagher J Controlled trial of lamotrigine (Lamictal) for treatment-resistant partial seizures. Acta Neurol Scand 1996, 94:247-252.
20. Schachter SC, Leppik IE, Matsuo F, et al. Lamotrigine: a six-month, placebo-controlled, safety and tolerance study. J Epilepsy 1995, 8:201-209.
21. Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000, 41:1597-1607.
22. Richens A, Mawer G, Crawford P, Harrison B A placebo-controlled, double-blind cross-over trial of adjunctive one month remacemide hydrochloride treatment in patients with refractory epilepsy. Seizure 2000, 9:537-543.
23. Elger C, Halasz P, Maia J, Almeida L, Soares-da-Silva P Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009, 50:454-463.
24. Sackellares JC, Ramsay RE, Wilder BJ, Browne TR, Shellenberger MK Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004, 45:610-617.
25. Brodie MJ, Rosenfeld WE, Vazquez B, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009, 50:1899-1909.
26. Brodie MJ, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010, 75:1817-1824.
27. Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005, 46:31-41.
28. Bauer J, Dienel A, Elger CE Losigamone add-on therapy in partial epilepsy: a placebo-controlled study. Acta Neurol Scand 2001, 103:226-230.
29. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000, 55:236-242.
30. Kerr MP, Baker GA, Brodie MJ A randomized, double-blind, placebo-controlled trial of topiramate in adults with epilepsy and intellectual disability: impact on seizures, severity, and quality of life. Epilepsy Behav 2005, 7:472-480.
31. Chadwick DW, Betts TA, Boddie HG, et al. Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 1200 mg/day) in a Q.I.D. regimen. Seizure 2002, 11:114-123.
32. Chadwick D, Leiderman DB, Sauermann W, Alexander J, Garofalo E Gabapentin in generalized seizures. Epilepsy Res 1996, 25:191-197.
33. Boon P, Chauvel P, Pohlmann-Eden B, Otoul C, Wroe S Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Res 2002, 48:77-89.
34. French JA, Mansbach H 1200 mg/day Retigabine as adjunctive therapy in adults with refractory partial-onset seizures. Epilepsia 2008, 49:112-113.
35. Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007, 68:1197-1204.
36. Mikkelsen B, Birket-Smith E, Holm P, Lund M, Vestermark S, Olsen PZ A controlled trial on clonazepam INN (Ro 5-4023, Rivotril (R)) in the treatment of focal epilepsy and secondary generalized grand mal epilepsy. Acta Neurol Scand Suppl 1975, 60:55-61.
37. Dodrill CB, Arnett JL, Sommerville KW, Sussman NM Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology 1993, 43:2501-2507.
38. Leestma JE, Annegers JF, Brodie MJ, et al. Sudden unexplained death in epilepsy: observations from a large clinical development program. Epilepsia 1997, 38:47-55.
39. Racoosin JA, Feeney J, Burkhart G, Boehm G Mortality in antiepileptic drug development programs. Neurology 2001, 56:514-519.
40. French JA Can evidence-based guidelines and clinical trials tell us how to treat patients?. Epilepsia 2007, 48:1264-1267.
41. Kwan P, Brodie MJ Early identification of refractory epilepsy. N Engl J Med 2000, 342:314-319.
42. Rheims S, Perucca E, Cucherat M, Ryvlin P Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia 2011, 52:219-233.
43. Perucca E, Tomson T The pharmacological treatment of epilepsy in adults. Lancet Neurol 2011, 10:446-456.